Drugs / AMG 199
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04117958 | Jan 2020 → Jun 2023 | cancer | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 199 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04117958 ↗ |
| Target | MUC17 | “designed to direct T cells towards MUC17-expressing cells” NCT04117958 ↗ |